Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
Antimicrob Agents Chemother
; 64(11)2020 10 20.
Artículo
en Inglés
| MEDLINE | ID: covidwho-738379
ABSTRACT
Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir's metabolite (GS-441524) and sulfobutylether ß-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19).
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Neumonía Viral
/
Pirroles
/
Triazinas
/
Adenosina Monofosfato
/
Infecciones por Coronavirus
/
Beta-Ciclodextrinas
/
Alanina
/
Betacoronavirus
/
Furanos
Tipo de estudio:
Estudio experimental
Idioma:
Inglés
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
AAC.01521-20
Similares
MEDLINE
...
LILACS
LIS